SET expression in clinical samples of 163 NSCLC and 42 adjacent normal tissues was determined by immunohistochemistry analysis: SET was overexpressed in 91.4% of tumor samples (149/163), whereas the adjacent normal tissues exhibited undetectable or low SET staining, showing that SET is a significant molecule in lung cancer development. This evidence concerns the gene SET and lung carcinoma.